Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.

London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN.

Exp Hematol. 1999 Apr;27(4):689-97.

PMID:
10210327
2.

Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs.

Zavodovskaya R, Chien MB, London CA.

J Vet Intern Med. 2004 Nov-Dec;18(6):915-7.

3.

Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.

Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y.

Blood. 1996 Jan 1;87(1):273-83.

4.

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.

Downing S, Chien MB, Kass PH, Moore PE, London CA.

Am J Vet Res. 2002 Dec;63(12):1718-23.

PMID:
12492288
5.

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, et al.

J Clin Invest. 1993 Oct;92(4):1736-44.

6.

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.

Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H.

Vet Immunol Immunopathol. 2010 Oct 15;137(3-4):208-16. doi: 10.1016/j.vetimm.2010.05.009. Epub 2010 May 31.

PMID:
20591500
7.

Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.

Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M.

Vet Immunol Immunopathol. 2006 Nov 15;114(1-2):168-72. Epub 2006 Sep 5.

PMID:
16908071
8.

Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.

Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y.

Blood. 1994 May 1;83(9):2619-26.

9.

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.

Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y.

Int Arch Allergy Immunol. 1995 Apr;106(4):377-85.

PMID:
7536501
10.

Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.

Zemke D, Yamini B, Yuzbasiyan-Gurkan V.

Vet Pathol. 2002 Sep;39(5):529-35.

11.
12.

Canine mast cell tumors express stem cell factor receptor.

Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L.

Am J Dermatopathol. 2000 Feb;22(1):49-54.

PMID:
10698217
13.

Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.

Ohmori K, Kawarai S, Yasuda N, Tanaka A, Matsuda H, Nishimura R, Sasaki N, Tsujimoto H, Masuda K.

Vet Immunol Immunopathol. 2008 Nov 15;126(1-2):43-53. doi: 10.1016/j.vetimm.2008.06.014. Epub 2008 Jul 5.

PMID:
18687474
14.

Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.

Zavodovskaya R, Liao AT, Jones CL, Yip B, Chien MB, Moore PF, London CA.

Am J Vet Res. 2006 Apr;67(4):633-41.

PMID:
16579756
15.

Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours.

London CA, Kisseberth WC, Galli SJ, Geissler EN, Helfand SC.

J Comp Pathol. 1996 Nov;115(4):399-414.

PMID:
9004081
16.
17.

Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.

Sundström M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD, Nilsson G.

Immunology. 2003 Jan;108(1):89-97.

18.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.

Clin Cancer Res. 2003 Nov 15;9(15):5729-34.

19.

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA.

Blood. 2002 Jul 15;100(2):585-93. Erratum in: Blood 2002 Oct 15;100(8):2696.

20.
Items per page

Supplemental Content

Write to the Help Desk